A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for catalase and urease and negative for oxidase, alkaline phosphatase and coagulase. It can ferment sucrose, mannitol, fructose, and lactose but not arabinose, cellobiose, turanose, xylose, or xylitol. S. simulans is found on human and animal skin and is a pathogen that can cause bumble foot disease and mastitis in animals and ostomyelitis and prosthesis related infections in humans.


A species of Gram-positive, alpha- or beta-hemolytic bacteria in the order Lactobacillales. The species is split into two subspecies, S. dysgalactiae subsp. dysgalactiae and S. dysgalactiae subsp. equisimilis.


A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is catalase negative, leucine aminopeptidase and pyrrolidonylarylamidase positive, grows in 6.5% NaCl and hydrolyzes esculin. It can ferment salicin, inulin, trehalose, mannitol, and sorbitol but not raffinose. S. uberis is found in a wide variety of environments and may cause mastitis in cows, but is not known to be a human pathogen.


A non taxonomic grouping of species within the Streptococcus genus that are alpha hemolytic and do not express Lancefield antigens.


A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is alpha hemolytic, hydrolyzes esculin and is negative for arginine deaminase, and catalase. It can ferment inulin, salicin, and raffinose but not mannitol, or sorbitol. S. salivarius is found in the normal flora of the mouth and respiratory tract and is rarely a human pathogen causing opportunistic infections.


A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is alpha hemolytic, catalase and arginine deaminase negative, does not grow in 6.5% NaCl and does not hydrolyze esculin. It can ferment fructose, glucose, lactose, mannose and sucrose but not amygdalin, arabinose, cellobiose, inulin, maltose, mannitol, salicin, sorbitol, trehalose and xylose. S. thermophilus is found in milk and milk products, used to manufacture cheese and yogurt and is not known to be a human pathogen.


The type species of the genus BARTONELLA, a gram-negative bacteria found in humans. It is found in the mountain valleys of Peru, Ecuador, and Southwest Columbia where the sandfly (see PHLEBOTOMUS) vector is present. It causes OROYA FEVER and VERRUGA PERUANA.


Species of gram-negative bacteria in the family ANAPLASMATACEAE, causing EHRLICHIOSIS in DOGS. The most common vector is the brown dog tick. It can also cause disease in humans.


A species of gram-negative bacteria in the genus ANAPLASMA, family ANAPLASMATACEAE, formerly called Ehrlichia phagocytophila or Ehrlichia equi. This organism is tick-borne (IXODES) and causes disease in horses and sheep. In humans, it causes human granulocytic EHRLICHIOSIS.


A dimorphic, homothallic and hemiascomycetous yeast in the phylum Ascomycota. This species is respiro-fermentative, Crabtree negative, thermotolerant, and assimilate lactose and insulin. This species also has a characteristically high growth rate and secretory capacity. K. marxianus is a biocatalyst and used industrially to produce beta-galactosidase, beta-glucosidase, inulinase, and polygalacturonases. It is also used as baker's yeast and an anticholesterolemic agent.


A species of yeast in the genus Candida.


A species of zoophilic and dermatophytic fungi in the phylum Ascomycota. This species causes ringworm in cattle.


Robinul Forte 2 MG Oral Tablet
Robinul 2 MG Oral Tablet

glycopyrrolate 2 MG Oral Tablet [Robinul]


Emetrol (dextrose 1.87 GM / fructose 1.87 GM / phosphoric acid 21.5 MG) per 5 ML Oral Solution

Emetrol (sucrose 3.74 GM / phosphoric acid 21.5 MG) per 5 ML Oral Solution

Emetrol 1.87 GM / 1.87 GM / 21.5 MG in 5 mL Oral Solution

fructose 374 MG/ML / glucose 374 MG/ML / phosphoric acid 4.3 MG/ML Oral Solution [Emetrol]


Golytely (polyethylene glycol 3350 227.1 GM / potassium chloride 2.82 GM / sodium bicarbonate 6.36 GM / sodium chloride 5.53 GM / sodium sulfate 21.5 GM) Powder for Oral Solution

GoLYTELY Packet Powder for Oral Solution

POLYETHYLENE GLYCOL 3350 227100 MG / K+ Chloride 2820 MG / NaHCO3 6360 MG / NaCl 5530 MG / sodium sulfate 21500 MG Powder for Oral Solution [Golytely]

polyethylene glycol 3350 227100 MG / potassium chloride 2820 MG / sodium bicarbonate 6360 MG / sodium chloride 5530 MG / sodium sulfate 21500 MG Powder for Oral Solution [Golytely]

POLYETHYLENE GLYCOL 3350 227100 MG / Pot Chloride 2820 MG / NaHCO3 6360 MG / NaCl 5530 MG / sodium sulfate 21500 MG Powder for Oral Solution [Golytely]


Cortenema 100 MG per 60 mL Enema
Cortenema 100 MG per 60 ML Enema
Cortenema 1.67 MG/ML Enema

hydrocortisone 1.67 MG/ML Enema [Cortenema]


The fumarate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion.


The hydrobromide salt form of dextromethorphan, a synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.


ASA 228 MG Chewing Gum [Aspergum]
Aspergum 227.5 MG Chewing Gum


dihydroergotamine mesylate 1 MG Oral Tablet


Lincocin (as lincomycin HCl) 300 MG/ML Injectable Solution

lincomycin 300 MG/ML Injectable Solution [Lincocin]


250 ML Foscavir 24 MG/ML Injection
Foscavir 6000 MG in 250 mL Injection
Foscavir 6000 MG per 250 ML Injection

250 ML foscarnet sodium 24 MG/ML Injection [Foscavir]


An orally bioavailable sulfonamide urea derivative with antihyperglycemic activity. Upon administration, glibornuride binds to and blocks the sulfonylurea receptor type 1 (SUR1) subunit of the ATP-sensitive inwardly-rectifying potassium (K(ATP)) channels on the membranes of pancreatic beta cells. This prevents the inward flow of positively charged potassium (K+) ions into the cell, and induces a calcium ion (Ca2+) influx through voltage-sensitive calcium channels, which triggers exocytosis of insulin-containing granules. Insulin stimulates glycogen synthesis and inhibits gluconeogenesis, which together lower blood glucose levels.


A sulfapyrimidine derivative,also known as glycodiazine, with antihyperglycemic activity. Like sulfonylureas, glymidine is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells and increasing the sensitivity of peripheral tissues to insulin.


Kenalog-40 40 MG/ML Injectable Suspension

triamcinolone acetonide 40 MG/ML Injectable Suspension [Kenalog]


phenazopyridine hydrochloride 100 MG Oral Tablet [Pyridium]


calcium 78 MG Oral Tablet, as calcium lactate

calcium lactate 600 MG (calcium 78 MG) Oral Tablet


sulfacetamide sodium 20 % Ophthalmic Solution

sulfacetamide sodium 200 MG/ML Ophthalmic Solution


sulfacetamide sodium 2.5 % Ophthalmic Ointment

sulfacetamide sodium 0.025 MG/MG Ophthalmic Ointment


sulfacetamide sodium 6 % Ophthalmic Ointment

sulfacetamide sodium 0.06 MG/MG Ophthalmic Ointment


physostigmine salicylate 0.25 % / pilocarpine hydrochloride 4 % Ophthalmic Solution

physostigmine salicylate 0.25 % / pilocarpine HCl 4 % Ophthalmic Solution

physostigmine salicylate 2.5 MG/ML / pilocarpine hydrochloride 40 MG/ML Ophthalmic Solution


physostigmine salicylate 0.5 % / pilocarpine HCl 4 % Ophthalmic Solution

physostigmine salicylate 0.5 % / pilocarpine hydrochloride 4 % Ophthalmic Solution

physostigmine salicylate 5 MG/ML / pilocarpine hydrochloride 40 MG/ML Ophthalmic Solution


sodium chloride 0.9 % Ophthalmic Irrigation Solution

NaCl 0.154 MEQ/ML Ophthalmic Irrigation Solution

sodium chloride 0.154 MEQ/ML Ophthalmic Irrigation Solution


gentamicin (as gentamicin sulfate) 3 MG/ML / hydrocortisone acetate 10 MG/ML Otic Suspension

gentamicin 0.3 % / hydrocortisone acetate 1 % Otic Suspension

gentamicin 3 MG/ML / hydrocortisone acetate 10 MG/ML Otic Suspension


hydrocortisone 0.025 MG/MG Topical Ointment


Tridesilon 0.05 % Topical Cream
Tridesilon 0.5 MG/ML Topical Cream

desonide 0.5 MG/ML Topical Cream [Tridesilon]


SYNALAR 0.025 % Topical Ointment
Synalar 0.00025 MG/MG Topical Ointment
Synalar 0.025 % Topical Ointment

fluocinolone acetonide 0.00025 MG/MG Topical Ointment [Synalar]


fluocinolone acetonide 0.00625 % Topical Cream

fluocinolone acetonide 0.0625 MG/ML Topical Cream


fluocinolone acetonide 0.0025 % Topical Cream

fluocinolone acetonide 0.025 MG/ML Topical Cream


fluocinolone acetonide 0.1 MG/ML Topical Cream

fluocinolone acetonide 0.01 % Topical Cream


fluocinonide 0.0005 MG/MG Topical Ointment


fluocortolone caproate 0.0025 MG/MG / fluocortolone pivalate 0.0025 MG/MG Topical Ointment


The butyrate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leading to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.


Bactroban 0.02 MG/MG Topical Ointment
Bactroban 20 MG/GM Topical Ointment
Bactroban 2 % Topical Ointment
BACTROBAN 2 % Topical Ointment

mupirocin 0.02 MG/MG Topical Ointment [Bactroban]


nitrofurazone 0.002 MG/MG Topical Ointment


econazole nitrate 10 MG per 1 GM Topical Cream

econazole nitrate 10 MG/ML Topical Cream


acycycloguanosine 50 MG/ML Topical Cream [Zovirax]

acyclovir 50 MG/ML Topical Cream [Zovirax]


The hydrochloride salt of a synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors such as the mu-opioid receptor, thereby producing characteristic morphine-like effects including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.


levamisole (as levamisole hydrochloride) 50 MG Oral Tablet


The sodium salt form of danaparoid, a synthetic low molecular weight heparin (LMWH) derived from porcine gut mucosa with anticoagulant activity. Danaparoid sodium binds to antithrombin III and inhibits the activity of activated factor X (factor Xa) and, to a lesser extent, activated factor II (thrombin) thereby preventing fibrin formation. Compared to heparin, danaparoid sodium exhibits a much higher ratio of anti-factor Xa activity to anti-factor IIa activity (22:1).


medroxyPROGESTERone acetate 2.5 MG Oral Tablet [Provera]

medroxyprogesterone acetate 2.5 MG Oral Tablet [Provera]


acycycloguanosine 80 MG/ML Oral Suspension

acyclovir 400 MG per 5 ML Oral Suspension


aspirin 150 MG Rectal Suppository
ASA 150 MG Rectal Suppository


The benzoate ester of metronidazole, a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities.


metroNIDAZOLE 25 % Oral Gel
metronidazole 25 % Oral Gel
metroNIDAZOLE 0.25 MG/MG Oral Gel
metroNIDAZOLE benzoate 25 % Oral Gel


rifabutin 150 MG Oral Capsule [Mycobutin]


Lescol (as fluvastatin sodium) 20 MG Oral Capsule


Lescol (as fluvastatin sodium) 40 MG Oral Capsule


Children's ZyrTEC 5 MG per 5 ML Medicated Spoon

Children's Zyrtec 5 MG per 5 ML Medicated Spoon

cetirizine hydrochloride 1 MG/ML Oral Solution [ZyrTEC]

cetirizine hydrochloride 1 MG/ML Oral Solution [Zyrtec]


morphine sulfate 5 MG/ML Oral Suspension


morphine sulfate 6.67 MG/ML Oral Suspension


Ciloxan 3 MG/ML (ciprofloxacin hydrochloride 3.5 MG/ML) Ophthalmic Solution

ciprofloxacin 3 MG/ML Ophthalmic Solution [Ciloxan]


aspirin 75 MG Delayed Release Oral Tablet


alprostadil 0.02 MG Injection [Caverject]


fluticasone propionate 0.05 % Topical Cream

fluticasone propionate 0.5 MG/ML Topical Cream


lamoTRIgine 100 MG Disintegrating Oral Tablet

lamotrigine 100 MG Disintegrating Oral Tablet


traMADol hydrochloride 50 MG Oral Capsule

tramadol hydrochloride 50 MG Oral Capsule


An orally available combination of carbidopa, an inhibitor of aromatic amino acid decarboxylation, and levodopa, an inert, metabolic precursor to dopamine, with dopaminergic and antiparkinsonian properties. Upon oral administration, levodopa crosses the blood-brain barrier (BBB) and is decarboxylated to dopamine via dopa decarboxylase in the brain, promoting increased activation of dopamine receptors. Carbidopa inhibits dopa decarboxylase in the periphery, thereby preventing decarboxylation of levodopa in extracerebral tissues and increasing the delivery of dopamine to the central nervous system (CNS). As carbidopa does not cross the BBB, it does not interfere with CNS levodopa metabolism.


methylTESTOSTERone / pemoline / yohimbine

methyltestosterone / pemoline / yohimbine


magnesium hydroxide 415 MG per 5 ML Oral Suspension

magnesium hydroxide 83 MG/ML Oral Suspension


sodium bicarbonate 600 MG Oral Tablet
NaHCO3 600 MG Oral Tablet


sodium bicarbonate 500 MG Oral Capsule
NaHCO3 500 MG Oral Capsule


hydrotalcite 500 MG per 5 ML Oral Suspension


aluminum hydroxide 600 MG / magnesium hydroxide 300 MG Oral Tablet

aluminum hydroxide 600 MG / milk of magnesia 300 MG Oral Tablet


dicyclomine HCl 10 MG in 5 mL Oral Solution

dicyclomine HCl 10 MG per 5 ML Oral Solution

dicyclomine hydrochloride 2 MG/ML Oral Solution


Pro-Banthine 15 MG Oral Tablet
Probanthine 15 MG Oral Tablet

propantheline 15 MG Oral Tablet [Probanthine]


Tagamet 200 MG Oral Tablet
Tagamet HB 200 MG Oral Tablet


cimetidine 400 MG Effervescent Oral Tablet


ranitidine 25 MG/ML Injectable Solution [Zantac]

raNITIdine 25 MG/ML Injectable Solution [Zantac]


Pepcid 20 MG Oral Tablet
Pepcid AC 20 MG Oral Tablet


Pepcid AC 40 MG Oral Tablet
Pepcid 40 MG Oral Tablet


miSOPROStol 0.2 MG Oral Tablet [Cytotec]

misoprostol 0.2 MG Oral Tablet [Cytotec]


codeine phosphate 10 MG / kaolin 3 G per 10 ML Oral Suspension

codeine phosphate 1 MG/ML / kaolin 300 MG/ML Oral Suspension


loperamide hydrochloride 2 MG Oral Capsule [Imodium]


Asacol 400 MG Delayed Release Oral Tablet

mesalamine 400 MG Delayed Release Oral Tablet [Asacol]


sulfaSALAzine 250 MG per 5 ML Oral Suspension

sulfasalazine 250 MG per 5 ML Oral Suspension


sulfasalazine 3 GM per 100 ML Enema
sulfaSALAzine 3 GM per 100 ML Enema
sulfaSALAzine 3 GM per 100 mL Enema
sulfaSALAzine 30 MG/ML Enema


The sodium salt form of olsalazine with anti-inflammatory activity. Olsalazine sodium is bioconverted to 5-aminosalicylic acid (5-ASA) in the colon by colonic bacteria. 5-ASA has anti-inflammatory activity in ulcerative colitis.


olsalazine sodium 250 MG Oral Capsule [Dipentum]


The husk of the dried ripe seeds of the Plantago psyllium, P. Indica, P. Ovata, and P. Arenaria plants with laxative and cholesterol lowering activities. The husks contain mucilage that swells on exposure to water and provides an indigestible mucilaginous mass in the intestines, thereby causing lubrication, contraction of the smooth muscles of the intestinal walls, and thus stimulating bowel movement. Psyllium husk is rich in soluble fiber and has a cholesterol-lowering effect.


picosulfate sodium 0.0667 MG/ML Oral Solution


lactulose 3.35 GM per 5 ML Oral Solution


digoxin 500 MCG in 2 ML Injection
digoxin 500 MCG per 2 ML Injection


bumetanide 0.5 MG/ML Injectable Solution


spironolactone 5 MG per 5 ML Oral Suspension


spironolactone 10 MG per 5 ML Oral Suspension


spironolactone 25 MG per 5 ML Oral Suspension

spironolactone 25 MG in 5 mL Oral Suspension


spironolactone 50 MG per 5 ML Oral Suspension


triamterene 50 MG / benzthiazide 25 MG Oral Capsule

benzthiazide 25 MG / triamterene 50 MG Oral Capsule


triamterene 50 MG / chlorthalidone 50 MG Oral Tablet

chlorthalidone 50 MG / triamterene 50 MG Oral Tablet


amiodarone hydrochloride 200 MG Oral Tablet [Cordarone]


verapamil hydrochloride 40 MG per 5 ML Oral Solution

verapamil hydrochloride 8 MG/ML Oral Solution


disopyramide (as disopyramide phosphate) 250 MG Extended Release Oral Capsule

disopyramide 250 MG Extended Release Oral Capsule


labetalol hydrochloride 100 MG Oral Tablet [Trandate]


labetalol hydrochloride 200 MG Oral Tablet [Trandate]


sotalol hydrochloride 200 MG Oral Tablet


aMILoride hydrochloride 2.5 MG / hydroCHLOROthiazide 25 MG / timolol maleate 10 MG Oral Tablet

timolol maleate 10 MG / aMILoride 2.5 MG / hydroCHLOROthiazide 25 MG Oral Tablet

aMILoride hydrochloride 2.5 MG / HCTZ 25 MG / timolol maleate 10 MG Oral Tablet

amiloride hydrochloride 2.5 MG / HCTZ 25 MG / timolol maleate 10 MG Oral Tablet

amiloride hydrochloride 2.5 MG / hydrochlorothiazide 25 MG / timolol maleate 10 MG Oral Tablet


acebutolol 200 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet

acebutolol (as acebutolol HCl) 200 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet

Acebutolol 200 MG / HCTZ 12.5 MG Oral Tablet

acebutolol (as acebutolol HCl) 200 MG / hydrochlorothiazide 12.5 MG Oral Tablet

acebutolol 200 MG / hydrochlorothiazide 12.5 MG Oral Tablet


aMILoride hydrochloride 2.5 MG / atenolol 50 MG / hydroCHLOROthiazide 25 MG Oral Capsule

aMILoride hydrochloride 2.5 MG / atenolol 50 MG / HCTZ 25 MG Oral Capsule

atenolol 50 MG / aMILoride HCl 2.5 MG / hydroCHLOROthiazide 25 MG Oral Capsule

amiloride hydrochloride 2.5 MG / atenolol 50 MG / HCTZ 25 MG Oral Capsule

amiloride hydrochloride 2.5 MG / atenolol 50 MG / hydrochlorothiazide 25 MG Oral Capsule


Cardura (as doxazosin mesylate) 1 MG Oral Tablet


Cardura (as doxazosin mesylate) 2 MG Oral Tablet


Cardura 4 MG Oral Tablet
doxazosin 4 MG Oral Tablet [Cardura]

Cardura 4 MG (as doxazosin mesylate) Oral Tablet


captopril 25 MG / HCTZ 12.5 MG Oral Tablet

captopril 25 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet

captopril 25 MG / hydrochlorothiazide 12.5 MG Oral Tablet


Zestril 2.5 MG Oral Tablet
Zestril 2.5 MG Oral Tablet, Once-Daily


Zestril 10 MG Oral Tablet, Once-Daily
Zestril 10 MG Oral Tablet


Zestril 20 MG Oral Tablet, Once-Daily
Zestril 20 MG Oral Tablet


diltiazem hydrochloride 60 MG 12 HR Extended Release Oral Tablet

dilTIAZem hydrochloride 60 MG 12 HR Extended Release Oral Tablet

12 HR dilTIAZem hydrochloride 60 MG Extended Release Oral Tablet

dilTIAZem HCl 60 MG 12HR Extended Release Oral Tablet

12 HR diltiazem hydrochloride 60 MG Extended Release Oral Tablet


The besylate salt of amlodipine, a synthetic dihydropyridine with antihypertensive and antianginal effects. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.


Plendil 10 MG 24 HR Extended Release Oral Tablet

24 HR Plendil 10 MG Extended Release Oral Tablet

Plendil 10 MG 24HR Extended Release Oral Tablet

24 HR felodipine 10 MG Extended Release Oral Tablet [Plendil]


isosorbide dinitrate 0.5 MG/ML Injectable Solution


isosorbide dinitrate 1.25 MG/ACTUAT Oral Spray


isosorbide dinitrate 1 MG/ML Injectable Solution


epinephrine 1 MG per 10 ML Prefilled Syringe

EPINEPHrine 1 MG in 10 ML Prefilled Syringe

EPINEPHrine 1 MG per 10 ML Prefilled Syringe

10 ML epinephrine 0.1 MG/ML Prefilled Syringe

10 ML EPINEPHrine 0.1 MG/ML Prefilled Syringe


The sodium salt form of epoprostenol, a synthetic prostacyclin, a member of the family of prostaglandins, with vasodilatory and anticoagulant activity. Epoprostenol sodium directly simulates prostaglandin receptors in arterial vascular smooth muscle, thereby causing vasodilatation. This agent also inhibits platelet aggregation by antagonizing platelet glycoprotein (GP) IIb/IIIa receptors, thereby preventing thrombus formation.


The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis.


aspirin 75 MG Oral Tablet
ASA 75 MG Oral Tablet


aspirin 75 MG Disintegrating Oral Tablet


A hydrochloride salt form of colestipol, a positively charged, non-digestible, triamine and epoxypropane copolymer anion-exchange resin that binds to bile acids in the intestine to form an insoluble complex, which is excreted in the feces.


A niacin derivative with antilipidemic activity.


albuterol 400 MCG/ACTUAT Inhalation Powder


ePHEDrine hydrochloride 3 MG/ML Oral Solution

ePHEDrine hydrochloride 15 MG per 5 ML Elixir

ephedrine hydrochloride 15 MG per 5 ML Elixir

ephedrine hydrochloride 3 MG/ML Oral Solution


ePHEDrine hydrochloride 0.8 MG/ML Oral Solution

ePHEDrine hydrochloride 4 MG per 5 ML Oral Solution

ephedrine hydrochloride 4 MG per 5 ML Oral Solution

ephedrine hydrochloride 0.8 MG/ML Oral Solution


clemastine fumarate 1.34 MG (clemastine 1 MG) Oral Tablet


The hydrochloride salt of a synthetic methyl-piperidine derivative with antihistaminic and anti-serotoninergic properties. Cyproheptadine competes with free histamine (HA) for binding at HA-receptor sites, thereby competitively antagonizing histamine stimulation of HA-receptors in the gastrointestinal tract, large blood vessels, and bronchial smooth muscle. This agent also competes with free serotonin for binding at serotonin receptor sites. Cyproheptadine exhibits anticholinergic and sedative properties and has been shown to stimulate appetite and weight gain. (NCI04)


chloral hydrate 28.6 MG/ML Oral Solution


diazePAM 2 MG Oral Tablet [Valium]
Valium 2 MG Oral Tablet


Valium 5 MG Oral Tablet
diazePAM 5 MG Oral Tablet [Valium]


diazepam 10 MG Oral Tablet [Valium]
Valium 10 MG Oral Tablet


Ativan 1 MG Oral Tablet
LORazepam 1 MG Oral Tablet [Ativan]


busPIRone hydrochloride 5 MG Oral Tablet [Buspar]

buspirone hydrochloride 5 MG Oral Tablet [Buspar]


The hydrochloride salt form of chlorpromazine, a phenothiazine and traditional antipsychotic agent with anti-emetic activity. Chlorpromazine hydrochloride exerts its antipsychotic effect by blocking postsynaptic dopamine receptors in cortical and limbic areas of the brain, thereby preventing the excess of dopamine in the brain. This leads to a reduction in psychotic symptoms, such as hallucinations and delusions. Chlorpromazine hydrochloride appears to exert its anti-emetic activity by blocking the dopamine receptors in the chemical trigger zone (CTZ) in the brain, thereby relieving nausea and vomiting.


trifluoperazine (as trifluoperazine hydrochloride) 2 MG Extended Release Oral Capsule

trifluoperazine 2 MG Extended Release Oral Capsule


trifluoperazine (as trifluoperazine hydrochloride) 10 MG Extended Release Oral Capsule

trifluoperazine 10 MG Extended Release Oral Capsule


trifluoperazine 15 MG Extended Release Oral Capsule

trifluoperazine (as trifluoperazine hydrochloride) 15 MG Extended Release Oral Capsule


cloZAPine 25 MG Oral Tablet [Clozaril]
Clozaril 25 MG Oral Tablet


cloZAPine 100 MG Oral Tablet [Clozaril]
Clozaril 100 MG Oral Tablet


risperidone 1 MG Oral Tablet [Risperdal]

risperiDONE 1 MG Oral Tablet [RisperDAL]


risperiDONE 2 MG Oral Tablet [RisperDAL]

risperidone 2 MG Oral Tablet [Risperdal]


risperiDONE 3 MG Oral Tablet [RisperDAL]

risperidone 3 MG Oral Tablet [Risperdal]


risperiDONE 4 MG Oral Tablet [RisperDAL]

risperidone 4 MG Oral Tablet [Risperdal]


imipramine hydrochloride 10 MG Oral Tablet [Tofranil]


imipramine hydrochloride 25 MG Oral Tablet [Tofranil]


imipramine hydrochloride 5 MG/ML Oral Solution


maprotiline hydrochloride 10 MG Oral Tablet


Nardil (as phenelzine sulfate) 15 MG Oral Tablet


Parnate 10 MG (as tranylcypromine sulfate) Oral Tablet

tranylcypromine 10 MG Oral Tablet [Parnate]


Prozac 20 MG (fluoxetine HCl 22.4 MG) Oral Capsule

PROzac 20 MG (FLUoxetine HCl 22.4 MG) Oral Capsule


metoclopramide (as the monohydrochloride monohydrate) 5 MG per 5 ML Oral Solution

metoclopramide 5 MG in 5 mL Oral Solution

metoclopramide 5 MG per 5 ML Oral Solution


ondansetron 4 MG Disintegrating Oral Tablet

ondansetron (as ondansetron HCl) 4 MG Disintegrating Oral Tablet


Zofran 8 MG Oral Tablet
ondansetron 8 MG Oral Tablet [Zofran]

Zofran (as ondansetron hydrochloride dihydrate) 8 MG Oral Tablet


aspirin 300 MG Delayed Release Oral Tablet


APAP 120 MG per 5 ML Oral Solution
APAP 24 MG/ML Oral Solution
acetaminophen 120 MG per 5 ML Elixir


acetaminophen 500 MG / methionine 250 MG Oral Tablet

APAP 500 MG / Methionine 250 MG Oral Tablet


acetaminophen 500 MG / codeine phosphate 30 MG Effervescent Oral Tablet

APAP 500 MG / Codeine Phosphate 30 MG Effervescent Oral Tablet


morphine sulfate 3 % Injectable Solution

morphine sulfate 30 MG/ML Injectable Solution


morphine sulfate 30 MG Rectal Suppository


A synthetic opioid analgesic. Dihydrocodeine bitartrate mimics the actions of the endogenous opioid peptides due to its agonistic effects on the opioid receptors. Stimulation of the mu receptors produces the typical narcotic effects of analgesia, miosis, euphoria, respiratory depression, sedation, physical dependence and bradycardia. Dihydrocodeine bitartrate is twice as potent as codeine and has one third of the potency of morphine. This analgesic is used for the relief of moderate to moderately severe pain.


dipipanone 10 MG / cyclizine 30 MG Oral Tablet

cyclizine 30 MG / dipipanone 10 MG Oral Tablet


The hydrochloride salt form of pentazocine, a benzomorphan narcotic agonist-antagonist. Pentazocine hydrochloride binds to and activates kappa- and sigma-opioid receptors, resulting in sedation and analgesia. In addition, this agent antagonizes the mu-receptor. Pentazocine hydrochloride partially reverses opiate-induced cardiovascular, respiratory, and behavioral depression.


phenytoin sodium 300 MG Oral Capsule
DPH sodium 300 MG Oral Capsule


phenytoin sodium 25 MG Oral Capsule
DPH sodium 25 MG Oral Capsule


phenytoin sodium 50 MG Oral Capsule
DPH sodium 50 MG Oral Capsule


lamoTRIgine 100 MG Oral Tablet [LaMICtal]

lamotrigine 100 MG Oral Tablet [Lamictal]


lamotrigine 25 MG Oral Tablet [Lamictal]

lamoTRIgine 25 MG Oral Tablet [LaMICtal]


valproic acid 150 MG Delayed Release Oral Capsule


valproic acid 500 MG Delayed Release Oral Capsule


gabapentin 100 MG Oral Capsule [Neurontin]


gabapentin 300 MG Oral Capsule [Neurontin]


gabapentin 400 MG Oral Capsule [Neurontin]


carbidopa / levodopa Extended Release Oral Tablet [Sinemet]


bromocriptine 5 MG Oral Capsule [Parlodel]


selegiline hydrochloride 10 MG Oral Tablet


orphenadrine hydrochloride 10 MG/ML Oral Solution


The hydrochloride salt of naltrexone, a noroxymorphone derivative with competitive opioid antagonistic activity. Naltrexone and its metabolite 6-beta-naltrexol reverse the effects of opioids by binding to various opioid receptors in the central nervous system CNS), including the mu-, kappa- and gamma-opioid receptors; opioid effects of analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence are inhibited. Naltrexone is longer-acting and more potent compared to naloxone.


nicotine 5 MG per 16 HR Transdermal Patch

nicotine 7.5 MG per 24 HR Transdermal Patch

nicotine 0.313 MG/HR 24 HR Transdermal Patch

24 HR nicotine 0.313 MG/HR Transdermal System


lofexidine 0.18 MG (as lofexidine HCl 0.2 MG) Oral Tablet


penicillin G 375 MG/ML Injectable Solution


floxacillin (as floxacillin sodium) 167 MG/ML Injectable Solution

floxacillin 167 MG/ML Injectable Solution


floxacillin (as floxacillin sodium) 250 MG/ML Injectable Solution

floxacillin 250 MG/ML Injectable Solution


floxacillin (as floxacillin sodium) 400 MG/ML Injectable Solution

floxacillin 400 MG/ML Injectable Solution


amoxicillin 50 MG/ML / clavulanate 10 MG/ML Injectable Solution


cefadroxil 125 MG per 5 ML Oral Suspension

cefadroxil (as cefadroxil monohydrate) 25 MG/ML Oral Suspension


cefadroxil (as cefadroxil monohydrate) 100 MG/ML Oral Suspension

cefadroxil 500 MG in 5 mL Oral Suspension

cefadroxil 500 MG per 5 ML Powder for Oral Suspension


Claforan (cefotaxime sodium) 10 GM per 50 ML Injectable Solution

cefotaxime 200 MG/ML Injectable Solution [Claforan]


cilastatin 250 MG / imipenem 250 MG Injection [Primaxin]


Erythrocin Lactobionate 500 MG Injection

erythromycin lactobionate 500 MG Injection [Erythrocin]


Zithromax 200 MG in 5 mL Oral Suspension

Zithromax 200 MG per 5 ML Oral Suspension

azithromycin 40 MG/ML Oral Suspension [Zithromax]


chloramphenicol 125 MG per 5 ML Oral Suspension

chloramphenicol 25 MG/ML Oral Suspension


fusidate 250 MG per 5 ML Oral Suspension


INH 10 MG/ML Oral Solution
isoniazid 10 MG/ML Oral Solution
isoniazid 50 MG per 5 ML Oral Solution
isoniazid 50 MG per 5 ML Syrup


metronidazole 200 MG per 5 ML Oral Suspension

metronidazole (as metronidazole benzoate) 40 MG/ML Oral Suspension

metroNIDAZOLE 200 MG per 5 ML Oral Suspension

metroNIDAZOLE (as metroNIDAZOLE benzoate) 40 MG/ML Oral Suspension


flucytosine 10 MG/ML Injectable Solution


Lamisil (as terbinafine hydrochloride) 250 MG Oral Tablet

LamISIL (as terbinafine hydrochloride) 250 MG Oral Tablet

terbinafine 250 MG Oral Tablet [LamISIL]

terbinafine 250 MG Oral Tablet [Lamisil]


zidovudine 250 MG Oral Capsule
AZT 250 MG Oral Capsule


dapsone 100 MG / pyrimethamine 12.5 MG Oral Tablet


betamethasone 500 MCG Disintegrating Oral Tablet

betamethasone 0.5 MG Disintegrating Oral Tablet


Decadron 0.5 MG Oral Tablet
DECADRON 0.5 MG Oral Tablet

dexamethasone 0.5 MG Oral Tablet [Decadron]


Solu-Cortef (as hydrocortisone sodium succinate) 100 MG Injection

Solu-CORTEF (as hydrocortisone sodium succinate) 100 MG Injection

hydrocortisone 100 MG Injection [Solu-CORTEF]

hydrocortisone 100 MG Injection [Solu-Cortef]


methylPREDNISolone (as methylPREDNISolone sodium succinate) 1 GM Injection

methylprednisolone (as methylprednisolone sodium succinate) 1 GM Injection

methylPREDNISolone sodium succinate 1 GM Injection


prednisoLONE 2.5 MG Delayed Release Oral Tablet

prednisolone 2.5 MG Delayed Release Oral Tablet


prednisoLONE 5 MG Delayed Release Oral Tablet

prednisolone 5 MG Delayed Release Oral Tablet


prednisoLONE 5 MG Disintegrating Oral Tablet

prednisolone 5 MG Disintegrating Oral Tablet


desmopressin acetate 0.1 MG/ML Nasal Solution [DDAVP]

DDAVP Rhinal Tube 10 MCG per 0.1 ML Nasal Solution


The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.


Parlodel SnapTabs 2.5 MG Oral Tablet
Parlodel 2.5 MG Oral Tablet

bromocriptine 2.5 MG Oral Tablet [Parlodel]


metyraPONE 250 MG Oral Capsule [Metopirone]

metyrapone 250 MG Oral Capsule [Metopirone]


dinoprostone 1 MG/ML Injectable Solution


dinoprostone 10 MG/ML Injectable Solution


dinoprostone 3 MG Vaginal Drug Implant
dinoprostone 3 MG Vaginal Insert
PGE2 3 MG Drug Implant


Prostin VR Pediatric 500 MCG in 1 ML Injection

Prostin VR Pediatric 500 MCG per 1 ML Injection

1 ML alprostadil 0.5 MG/ML Injection [Prostin VR]


The hydrochloride salt form of ritodrine, a phenethylamine derivative with tocolytic activity. Ritodrine hydrochloride binds to and activates beta-2 adrenergic receptors of myocytes in the uterine myometrium, which results in decreased intensity and frequency of uterine contraction. Specifically, ritodrine hydrochloride probably activates adenyl cyclase, thereby increasing production of cyclic adenosine monophosphate (cAMP), which in turn enhancing the efflux of calcium from vascular smooth muscle cells. A lack of intracellular calcium prevents uterine myometrial contraction. In addition, this agent may directly inactivate myosin light chain kinase, a critical enzyme necessary for the initiation of muscle contractions.


estrogens, conjugated (USP) Vaginal Cream [Premarin]


flavoxATE hydrochloride 200 MG Oral Tablet

flavoxate hydrochloride 200 MG Oral Tablet


NaHCO3 13.1 MG/ML / sodium citrate 4.7 MG/ML Oral Solution

sodium bicarbonate 13.1 MG/ML / sodium citrate 4.7 MG/ML Oral Solution


methylTESTOSTERone 5 MG / pemoline 10 MG / yohimbine 5 MG Oral Capsule

yohimbine 5 MG / pemoline 10 MG / methylTESTOSTERone 5 MG Oral Capsule

methyltestosterone 5 MG / pemoline 10 MG / yohimbine 5 MG Oral Capsule


BiCNU 100 MG Injection
BCNU 100 MG Injection [BiCNU]


LEUKERAN Tablets 2 MG Oral Tablet
Leukeran 2 MG Oral Tablet

chlorambucil 2 MG Oral Tablet [Leukeran]


ALKERAN 2 MG Oral Tablet
Alkeran 2 MG Oral Tablet


Alkeran 50 MG Injection
ALKERAN 50 MG Injection


DACTINomycin 0.5 MG Injection [Cosmegen]

dactinomycin 0.5 MG Injection [Cosmegen]


5-5-fluorouracil 50 MG/ML Topical Cream
5-FU 50 MG/ML Topical Cream
fluorouracil 50 MG/ML Topical Cream


5-FU 250 MG Oral Capsule
5-5-fluorouracil 250 MG Oral Capsule
fluorouracil 250 MG Oral Capsule


methotrexate 2.5 MG (as methotrexate sodium) Oral Tablet


methotrexate (as methotrexate sodium) 100 MG/ML Injectable Solution

methotrexate 100 MG/ML Injectable Solution


hydroxyurea 500 MG Oral Capsule [Hydrea]


NIPENT 10 MG Injection
Nipent 10 MG Injection


Imuran 50 MG Oral Tablet
IMURAN 50 MG Oral Tablet
azaTHIOprine 50 MG Oral Tablet [Imuran]


Nolvadex 10 MG (tamoxifen citrate 15.2 MG) Oral Tablet


Zoladex 3.6 MG subcutaneous Drug Implant

Zoladex 3.6 MG (as goserelin acetate 3.8 MG) Drug Implant


Proleukin 1.3 MG Injection
Proleukin 22000000 UNT Injection
Proleukin 22,000,000 UNT Injection

aldesleukin 22000000 UNT Injection [Proleukin]


ferrous sulfate 150 MG / folic acid 500 MCG Extended Release Oral Capsule

FESO4 150 MG / folate 0.5 MG Extended Release Oral Capsule

ferrous sulfate 150 MG / folic acid 0.5 MG Extended Release Oral Capsule


ferrous fumarate 305 MG / folic acid 350 MCG Oral Capsule

Ferrous fumarate 305 MG / folate 0.35 MG Oral Capsule

ferrous fumarate 305 MG / folic acid 0.35 MG Oral Capsule


ferric ammonium citrate 80 MG / folic acid 500 MCG per 5 ML Syrup

ferric ammonium citrate 16 MG/ML / folate 0.1 MG/ML Oral Solution

ferric ammonium citrate 16 MG/ML / folic acid 0.1 MG/ML Oral Solution


ferric ammonium citrate 80 MG / folic acid 2.5 MG per 5 ML Syrup

ferric ammonium citrate 16 MG/ML / folate 0.5 MG/ML Oral Solution

ferric ammonium citrate 16 MG/ML / folic acid 0.5 MG/ML Oral Solution


vit-C 10 MG / ferrous gluconate 250 MG / folate 5 MG Oral Tablet

ferrous gluconate 250 MG / folic acid 5 MG / ascorbic acid 10 MG Oral Tablet

vitamin C 10 MG / ferrous gluconate 250 MG / folate 5 MG Oral Tablet

ferrous gluconate 250 MG (iron 30 MG) / folic acid 5 MG / vitamin C 10 MG Oral Tablet

ascorbic acid 10 MG / ferrous gluconate 250 MG / folic acid 5 MG Oral Tablet


A delayed-release formulation of iron supplement consisting of an iron atom bound by a polysaccharide molecule. Upon oral administration, there is delayed-release of iron and iron absorption in the stomach and small intestine. The absorbed iron combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin and transferrin, and is a component of many enzymes such as catalase, peroxidase, and cytochromes. The delayed-release of iron may minimize the gastrointestinal upset caused by iron supplements.


cyanocobalamin 0.05 MG Oral Tablet
cyanocobalamin 50 MCG Oral Tablet
vitamin B 12 50 MCG Oral Tablet


vitamin B12 35 MCG per 5 ML Oral Solution

cyanocobalamin 35 MCG per 5 ML Oral Solution

cyanocobalamin 0.007 MG/ML Oral Solution


leucovorin 7.5 MG/ML Injectable Solution


A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.


A recombinant therapeutic agent that is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes.


potassium chloride 500 MG Effervescent Oral Tablet

K+ Chloride 500 MG Effervescent Oral Tablet

Pot Chloride 500 MG Effervescent Oral Tablet


NaCl 300 MG Oral Tablet
sodium chloride 300 MG Oral Tablet


calcium gluconate 1 GM Effervescent Oral Tablet

calcium gluconate 1000 MG Effervescent Oral Tablet


calcium lactate 300 MG (calcium 39 MG) Oral Tablet

calcium 39 MG Oral Tablet, as calcium lactate


4-aminobenzoic acid 15 MG/ML Oral Solution


vitamin E 500 MG per 5 ML Oral Suspension

alpha tocopheryl acetate 500 MG per 5 ML Oral Suspension


trientine dihydrochloride 300 MG Oral Capsule


diclofenac sodium 0.25 MG/ML Oral Solution


diclofenac sodium 75 MG Extended Release Oral Tablet


mefenamic acid 50 MG per 5 ML Oral Suspension


naproxen 250 MG Delayed Release Oral Tablet


EC-Naprosyn 375 MG Delayed Release Oral Tablet

naproxen 375 MG Delayed Release Oral Tablet [Naprosyn]


naproxen 500 MG Delayed Release Oral Tablet [Naprosyn]

EC-Naprosyn 500 MG Delayed Release Oral Tablet


nabumetone 500 MG per 5 ML Oral Suspension


gold sodium thiomalate 20 MG/mL Injectable Solution

gold sodium thiomalate 20 MG/ML Injectable Solution


gold sodium thiomalate 4 % Injectable Solution

gold sodium thiomalate 40 MG/ML Injectable Solution


gold sodium thiomalate 100 MG/ML Injectable Solution


benzydamine hydrochloride 3 % Topical Cream

benzydamine hydrochloride 30 MG/ML Topical Cream


diclofenac sodium 0.01 MG/MG Topical Gel


dibromopropamidine isethionate 0.1 % Ophthalmic Solution

dibromopropamidine isethionate 1 MG/ML Ophthalmic Solution


clobetasone butyrate 0.1 % Ophthalmic Solution


The hydrochloride salt form of cyclopentolate, an anticholinergic drug. Administered in the eye, cyclopentolate hydrochloride blocks the acetylcholine receptor in the sphincter muscle of the iris and the ciliary muscle, thereby preventing contraction. This dilates the pupil, producing mydriasis, and prevents the eye from accommodating.


tetracaine hydrochloride 2 % Ophthalmic Solution

tetracaine hydrochloride 20 MG/ML Ophthalmic Solution


cocaine (as cocaine hydrochloride) 40 MG/ML Ophthalmic Solution


aluminum acetate 130 MG/ML Otic Solution


hydrocortisone 1 % / neomycin 0.5 % Topical Cream

neomycin 0.5 % / hydrocortisone 1 % Topical Cream

hydrocortisone 10 MG/ML / neomycin 5 MG/ML Topical Cream


choline 20 % / glycerin 12.6 % Otic Solution

choline 200 MG/ML / glycerin 126 MG/ML Otic Solution


carbamide peroxide 50 MG/ML Otic Solution


cromolyn sodium 2 % / xylometazoline HCl 0.025 % Nasal Spray

cromolyn sodium 20 MG/ML / xylometazoline 0.25 MG/ML Nasal Spray


The hydrochloride salt form of oxymetazoline, an imidazole derivative with a direct acting sympathomimetic property. Oxymetazoline binds to and activates alpha-2 adrenergic receptors. Upon nasal or ocular administration, oxymetazoline constricts the arterioles in the nose and eye, resulting in decreased nasal and conjunctival congestion, respectively.


chlorhexidine hydrochloride 0.1 % / neomycin 0.5 % Topical Cream

chlorhexidine HCl 0.1 % / neomycin 0.5 % Topical Cream

chlorhexidine hydrochloride 1 MG/ML / neomycin 5 MG/ML Topical Cream


benzydamine hydrochloride 0.15 % Oral Spray

benzydamine hydrochloride 1.5 MG/ML Oral Spray


carboxymethylcellulose 16.58 % Oral Paste

carboxymethylcellulose 0.166 MG/MG Oral Paste


anthraquinone glycoside 0.5 % / salicylic acid 1 % Mucous Membrane Topical Solution

anthraquinone glycoside 5 MG/ML / salicylic acid 10 MG/ML Mucous Membrane Topical Solution


benzalkonium chloride 500 MCG Oral Lozenge

benzalkonium chloride 0.5 MG Oral Lozenge


benzocaine 10 MG / cetylpyridinium chloride 1.4 MG Oral Lozenge


benzocaine 5 MG / tyrothricin 1 MG Oral Lozenge


benzocaine 2 % / chloroxylenol 0.106 % Oral Gel

benzocaine 0.02 MG/MG / chloroxylenol 0.00106 MG/MG Oral Gel


domiphen bromide 500 MCG / lidocaine HCl 5 MG Oral Lozenge

domiphen 0.5 MG / lidocaine hydrochloride 5 MG Oral Lozenge


chlorhexidine gluconate 0.2 % Oral Spray

chlorhexidine gluconate 2 MG/ML Oral Spray


chlorhexidine gluconate 0.05 % / tetracaine 0.015 % Oral Spray

chlorhexidine gluconate 0.5 MG/ML / tetracaine 0.15 MG/ML Oral Spray


chlorhexidine gluconate 0.1 % / chlorobutanol 0.5 % Mouthwash

chlorhexidine gluconate 1 MG/ML / chlorobutanol 5 MG/ML Mouthwash


mucin 63 MG / xylitol 39 MG Oral Lozenge

mucins 63 MG / xylitol 39 MG Oral Lozenge


lactic acid 5 % / urea 10 % Topical Cream

lactic acid 50 MG/ML / urea 100 MG/ML Topical Cream


benzocaine 1 % / triclosan 0.2 % Topical Spray

benzocaine 10 MG/ML / triclosan 2 MG/ML Topical Spray


benzocaine 1 % / triclosan 0.2 % Topical Lotion

benzocaine 10 MG/ML / triclosan 2 MG/ML Topical Lotion


benzocaine 1 % / triclosan 0.2 % Topical Cream

benzocaine 10 MG/ML / triclosan 2 MG/ML Topical Cream


clioquinol 3 % / hydrocortisone 1 % Topical Cream

clioquinol 30 MG/ML / hydrocortisone 10 MG/ML Topical Cream


hydrocortisone 1 % / clotrimazole 1 % Topical Cream

clotrimazole 1 % / hydrocortisone 1 % Topical Cream

clotrimazole 10 MG/ML / hydrocortisone 10 MG/ML Topical Cream


beclomethasone dipropionate 0.025 % Topical Cream

beclomethasone dipropionate 0.25 MG/ML Topical Cream


beclomethasone dipropionate 0.025 % Topical Ointment

beclomethasone dipropionate 0.00025 MG/MG Topical Ointment


betamethasone (as betamethasone valerate) 0.1 % / clioquinol 3 % Topical Ointment

betamethasone 0.1 % / clioquinol 3 % Topical Ointment

betamethasone 0.001 MG/MG / clioquinol 0.03 MG/MG Topical Ointment


betamethasone (as betamethasone valerate) 1 MG/ML / clioquinol 30 MG/ML Topical Cream

betamethasone 0.1 % / clioquinol 3 % Topical Cream

betamethasone 1 MG/ML / clioquinol 30 MG/ML Topical Cream


clobetasone butyrate 0.05 % Topical Cream

clobetasone butyrate 0.5 MG/ML Topical Cream


clobetasone butyrate 0.05 % Topical Ointment

clobetasone butyrate 0.0005 MG/MG Topical Ointment


chlorquinaldol 3 % / hydrocortisone butyrate 0.1 % Topical Ointment

hydrocortisone butyrate 0.1 % / chlorquinaldol 3 % Topical Ointment

chlorquinaldol 0.03 MG/MG / hydrocortisone butyrate 0.001 MG/MG Topical Ointment


chlorquinaldol 3 % / hydrocortisone butyrate 0.1 % Topical Cream

hydrocortisone butyrate 0.1 % / chlorquinaldol 3 % Topical Cream

chlorquinaldol 30 MG/ML / hydrocortisone butyrate 1 MG/ML Topical Cream


hydrocortisone butyrate 0.1 % Topical Ointment

hydrocortisone butyrate 0.001 MG/MG Topical Ointment

hydrocortisone butyrate 1 MG per GM Topical Ointment


hydrocortisone butyrate 1 MG/ML Topical Lotion [Locoid]


triamcinolone acetonide 0.1 % Topical Ointment

triamcinolone acetonide 0.001 MG/MG Topical Ointment


triamcinolone acetonide 1 MG per GM Topical Cream

triamcinolone acetonide 0.1 % Topical Cream

triamcinolone acetonide 1 MG/ML Topical Cream


hydrocortisone 1 GM per 100 GM Topical Cream

hydrocortisone 1 % (as hydrocortisone acetate 1.2 % ) Topical Cream


benzoyl peroxide 10 % / oxyquinoline sulfate 0.5 % Topical Cream

benzoyl peroxide 100 MG/ML / oxyquinoline sulfate 5 MG/ML Topical Cream


erythromycin 40 MG/ML / zinc acetate 12 MG/ML Topical Solution


benzoyl peroxide 50 MG/ML Topical Lotion


benzoyl peroxide 100 MG/ML Topical Lotion


benzoyl peroxide 100 MG/ML Topical Cream


A solution or suspension composed of active and inert ingredient(s) in an anionic surfactant and intended for administration to the hair and/or scalp.


povidone-iodine 40 MG/ML Medicated Shampoo


salicylic acid 3 % / sulfur 5 % Medicated Shampoo

salicylic acid 30 MG/ML / sulfur 50 MG/ML Medicated Shampoo


lithium succinate 0.08 MG/MG Topical Ointment


mupirocin 20 MG per GM Topical Ointment
mupirocin 2 % Topical Ointment


silver sulfadiazine 10 MG/ML Topical Cream

silver sulfADIAZINE 10 MG/ML Topical Cream


chlortetracycline HCl 3 % Topical Ointment

chlortetracycline 0.03 MG/MG Topical Ointment


tetracycline hydrochloride 0.03 MG/MG Topical Ointment


miconazole nitrate 0.0016 MG/MG Powder Spray


sulconazole nitrate 10 MG/ML Topical Cream


zinc undecylenate 20 % / undecylenic acid 5 % Topical Spray

undecylenic acid 50 MG/ML / zinc undecylenate 200 MG/ML Topical Spray


aluminum acetate 6.5 MG/ML Topical Lotion


chlorhexidine gluconate 1.5 % / cetrimide 15 % Topical Solution

cetrimide 15 % / chlorhexidine gluconate 1.5 % Topical Solution

cetrimide 150 MG/ML / chlorhexidine gluconate 15 MG/ML Topical Solution


chlorhexidine gluconate 0.1 % Topical Solution

chlorhexidine gluconate 1 MG/ML Topical Solution


chlorhexidine gluconate 0.05 % / cetrimide 0.5 % Topical Solution

cetrimide 0.5 % / chlorhexidine gluconate 0.05 % Topical Solution

cetrimide 5 MG/ML / chlorhexidine gluconate 0.5 MG/ML Topical Solution


chlorhexidine gluconate 0.05 % Topical Solution

chlorhexidine gluconate 0.5 MG/ML Topical Solution


povidone-iodine 40 MG/ML Topical Solution


povidone-iodine 0.025 MG/MG Powder Spray


Pot Permanganate 1 MG/ML Topical Solution

K+ Permanganate 1 MG/ML Topical Solution

potassium permanganate 0.1 % Topical Solution

potassium permanganate 1 MG/ML Topical Solution


hydrogen peroxide 15 MG/ML Topical Cream


purified protein derivative of tuberculin 100000 UNT/ML Injectable Solution


purified protein derivative of tuberculin 1000 UNT/ML Injectable Solution


varicella-zoster immune globulin 50 MG/ML Injectable Solution


alfentanil (as alfentanil hydrochloride) 5 MG/ML Injectable Solution


meptazinol (as meptazinol hydrochloride) 200 MG Oral Tablet


papaveretum 15.4 MG/ML / scopolamine 0.4 MG/ML Injectable Solution


midazolam 10 MG per 5 ML Injectable Solution

midazolam (as midazolam hydrochloride) 2 MG/ML Injectable Solution


glycopyrrolate 0.5 MG/ML / neostigmine 2.5 MG/ML Injectable Solution


1 ML naloxone hydrochloride 0.4 MG/ML Cartridge

naloxone hydrochloride 0.4 MG per 1 ML Cartridge


Xylocaine 5 MG/ML Injectable Solution
Xylocaine 0.5 % Injectable Solution

lidocaine hydrochloride 5 MG/ML Injectable Solution [Xylocaine]


lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine]


lidocaine hydrochloride 20 MG/ML Injectable Solution [Xylocaine]


Xylocaine 5 % Ointment for Oral and Topical Administration

Xylocaine 0.05 MG/MG Ointment for Oral and Topical Administration

lidocaine hydrochloride 0.05 MG/MG Topical Ointment [Xylocaine]


Xylocaine 40 MG/ML Mucous Membrane Topical Solution

Xylocaine 4 % Mucous Membrane Topical Solution

lidocaine hydrochloride 40 MG/ML Mucous Membrane Topical Solution [Xylocaine]


felypressin 0.03 UNT/ML / prilocaine hydrochloride 3 % Injectable Solution

felypressin 0.03 UNT/ML / prilocaine hydrochloride 30 MG/ML Injectable Solution


The hydrochloride salt form of procaine, a benzoic acid derivative with local anesthetic and antiarrhythmic properties. Procaine binds to and inhibits voltage-gated sodium channels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses. In addition, this agent increases electrical excitation threshold, reduces rate of rise of action potential and slows nerve impulse propagation thereby causing loss of sensation.


magnesium hydroxide Oral Suspension [Phillips Milk of Magnesia]


phenylephrine HCl 5 % Ophthalmic Solution

phenylephrine hydrochloride 5 % Ophthalmic Solution

phenylephrine hydrochloride 50 MG/ML Ophthalmic Solution


EPINEPHrine 0.5 % / guanethidine 3 % Ophthalmic Solution

epinephrine 0.5 % / guanethidine 3 % Ophthalmic Solution

EPINEPHrine 5 MG/ML / guanethidine 30 MG/ML Ophthalmic Solution

epinephrine 5 MG/ML / guanethidine 30 MG/ML Ophthalmic Solution


EPINEPHrine 2 MG/ML / guanethidine 10 MG/ML Ophthalmic Solution

epinephrine 0.2 % / guanethidine 1 % Ophthalmic Solution

EPINEPHrine 0.2 % / guanethidine 1 % Ophthalmic Solution

epinephrine 2 MG/ML / guanethidine 10 MG/ML Ophthalmic Solution


epinephrine 0.5 % / guanethidine 1 % Ophthalmic Solution

EPINEPHrine 0.5 % / guanethidine 1 % Ophthalmic Solution

EPINEPHrine 5 MG/ML / guanethidine 10 MG/ML Ophthalmic Solution

EPINEPHrine (as EPINEPHrine bitartrate) 5 MG/ML / guanethidine 10 MG/ML Ophthalmic Solution

epinephrine (as epinephrine bitartrate) 5 MG/ML / guanethidine 10 MG/ML Ophthalmic Solution

epinephrine 5 MG/ML / guanethidine 10 MG/ML Ophthalmic Solution


EPINEPHrine 0.1 % / guanethidine 0.5 % Ophthalmic Solution

EPINEPHrine (as EPINEPHrine bitartrate) 1 MG/ML / guanethidine 5 MG/ML Ophthalmic Solution

EPINEPHrine 1 MG/ML / guanethidine 5 MG/ML Ophthalmic Solution

epinephrine 0.1 % / guanethidine 0.5 % Ophthalmic Solution

epinephrine (as epinephrine bitartrate) 1 MG/ML / guanethidine 5 MG/ML Ophthalmic Solution

epinephrine 1 MG/ML / guanethidine 5 MG/ML Ophthalmic Solution


EPINEPHrine (as EPINEPHrine bitartrate) 0.5 MG/ML / guanethidine 2.5 MG/ML Ophthalmic Solution

epinephrine 0.05 % / guanethidine 0.25 % Ophthalmic Solution

EPINEPHrine 0.5 MG/ML / guanethidine 2.5 MG/ML Ophthalmic Solution

EPINEPHrine 0.05 % / guanethidine 0.25 % Ophthalmic Solution

epinephrine (as epinephrine bitartrate) 0.5 MG/ML / guanethidine 2.5 MG/ML Ophthalmic Solution

epinephrine 0.5 MG/ML / guanethidine 2.5 MG/ML Ophthalmic Solution


guanethidine 30 MG/ML Ophthalmic Solution


guanethidine 20 MG/ML Ophthalmic Solution


guanethidine 10 MG/ML Ophthalmic Solution


guanethidine 5 MG/ML Ophthalmic Solution


guanethidine 2.5 MG/ML Ophthalmic Solution


EPINEPHrine 0.5 MG/ML Ophthalmic Solution

epinephrine (as epinephrine bitartrate) 0.5 MG/ML Ophthalmic Solution

EPINEPHrine (as EPINEPHrine bitartrate) 0.5 MG/ML Ophthalmic Solution

epinephrine 0.5 MG/ML Ophthalmic Solution


EPINEPHrine 5 MG/ML Ophthalmic Solution
EPINEPHrine 0.5 % Ophthalmic Solution
epinephrine 0.5 % Ophthalmic Solution


acetylcysteine 50 MG/ML Ophthalmic Solution


acetylcysteine 200 MG/ML Ophthalmic Solution


chlorproMAZINE 300 MG Rectal Suppository

chlorpromazine 300 MG Rectal Suppository


scopolamine (as scopolamine hydrobromide) 1.25 MG/ML Ophthalmic Solution

scopolamine 1.25 MG/ML Ophthalmic Solution


scopolamine (as scopolamine hydrobromide) 5 MG/ML Ophthalmic Solution


ASA 500 MG / Glycine 133 MG Disintegrating Oral Tablet

aspirin 500 MG / glycine 133 MG Disintegrating Oral Tablet


APAP 450 MG / Caffeine 30 MG Oral Tablet

acetaminophen 450 MG / caffeine 30 MG Oral Tablet


APAP 450 MG / Caffeine 25 MG Oral Tablet

acetaminophen 450 MG / caffeine 25 MG Oral Tablet


APAP 5 MG/ML / Caffeine 0.65 MG/ML Oral Solution

acetaminophen 5 MG/ML / caffeine 0.65 MG/ML Oral Solution


acetaminophen 150 MG / sodium salicylate 100 MG Oral Tablet

APAP 150 MG / Sodium Salicylate 100 MG Oral Tablet


codeine phosphate 8 MG / aspirin 300 MG Oral Tablet

ASA 300 MG / Codeine Phosphate 8 MG Oral Tablet

aspirin 300 MG / codeine phosphate 8 MG Oral Tablet


cefuroxime (as cefuroxime sodium) 50 MG/ML Ophthalmic Solution


Penicillin V Pot 3 MG/ML Ophthalmic Solution

penicillin V potassium 0.3 % Ophthalmic Solution

Penicillin V K+ 3 MG/ML Ophthalmic Solution

penicillin V potassium 3 MG/ML Ophthalmic Solution


gentamicin sulfate 1.5 % Ophthalmic Solution

gentamicin (as gentamicin sulfate) 1.5 % Ophthalmic Solution


amphotericin B liposomal 50 MG Injection


miconazole nitrate 10 MG/ML Ophthalmic Solution


clobetasol propionate 0.05 % Topical Ointment

clobetasol propionate 0.0005 MG/MG Topical Ointment


edetic acid 3.7 MG/ML Ophthalmic Solution


Cortifoam 100 MG/ML Rectal Foam
cortifoam 10 % Rectal Foam
Cortifoam 10 % Rectal Foam

hydrocortisone acetate 100 MG/ML Rectal Foam [Cortifoam]


prednisoLONE 0.003 % Ophthalmic Solution

prednisolone (as prednisolone sodium phosphate) 0.03 MG/ML Ophthalmic Solution

prednisoLONE (as prednisoLONE sodium phosphate) 0.03 MG/ML Ophthalmic Solution

prednisoLONE 0.03 MG/ML Ophthalmic Solution

prednisolone 0.003 % Ophthalmic Solution

prednisolone 0.03 MG/ML Ophthalmic Solution


prednisoLONE (as prednisoLONE sodium phosphate) 0.1 MG/ML Ophthalmic Solution

prednisolone (as prednisolone sodium phosphate) 0.1 MG/ML Ophthalmic Solution

prednisoLONE 0.1 MG/ML Ophthalmic Solution

prednisolone 0.1 MG/ML Ophthalmic Solution


prednisoLONE (as prednisoLONE sodium phosphate) 0.3 MG/ML Ophthalmic Solution

prednisoLONE 0.3 MG/ML Ophthalmic Solution

prednisolone (as prednisolone sodium phosphate) 0.3 MG/ML Ophthalmic Solution

prednisolone 0.3 MG/ML Ophthalmic Solution


prednisolone (as prednisolone sodium phosphate) 1 MG/ML Ophthalmic Solution

prednisoLONE 1 MG/ML Ophthalmic Solution

prednisoLONE (as prednisoLONE sodium phosphate) 1 MG/ML Ophthalmic Solution

prednisolone 1 MG/ML Ophthalmic Solution


prednisoLONE (as prednisoLONE sodium phosphate) 3 MG/ML Ophthalmic Solution

prednisolone (as prednisolone sodium phosphate) 3 MG/ML Ophthalmic Solution

prednisoLONE 3 MG/ML Ophthalmic Solution

prednisolone 3 MG/ML Ophthalmic Solution


A preparation of purified, pasteurized, gamma globulin obtained by the immunization of rabbits with human thymocytes, with T-cell depleting and immunosuppressive activities. Upon administration, rabbit anti-thymocyte globulin (rATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which rATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion and reduction in T-cell activation and their cytotoxic activities. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease (GvHD).


lymphocyte immune globulin, anti-thymocyte globulin, rabbit 25 MG Injection

anti-thymocyte globulin (rabbit) 25 MG Injection

rabbit anti-human T-lymphocyte globulin 25 MG Injection


rabbit anti-human T-lymphocyte globulin 25 MG Injection [Thymoglobulin]


sodium chloride Ophthalmic Irrigation Solution


potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.45 % per 500 ML Injection

500 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML Injection

500 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML Injection

potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.45 % in 500 ML Injection

500 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection


calcium chloride 10 % in 10 ML Prefilled Syringe

10 ML calcium chloride 100 MG/ML Prefilled Syringe


ergocalciferol 250 MCG (10,000 UNT) Oral Tablet


phenylbutazone 100 MG Delayed Release Oral Tablet


benzocaine 2 % / salicylamide 5 % Topical Gel

benzocaine 0.02 MG/MG / salicylamide 0.05 MG/MG Topical Gel


heparinoids 0.2 % / salicylic acid 2 % Topical Cream

heparinoid 0.2 % / salicylic acid 2 % Topical Cream

heparinoids 2 MG/ML / salicylic acid 20 MG/ML Topical Cream


heparinoids 0.2 % / salicylic acid 2 % Topical Gel

heparinoids 0.002 MG/MG / salicylic acid 0.02 MG/MG Topical Gel


homatropine hydrobromide 0.125 % Ophthalmic Solution

homatropine hydrobromide 0.125 % Ophthalmic Drops

homatropine hydrobromide 1.25 MG/ML Ophthalmic Solution


homatropine hydrobromide 0.25 % Ophthalmic Solution

homatropine hydrobromide 0.25 % Ophthalmic Drops

homatropine hydrobromide 2.5 MG/ML Ophthalmic Solution


homatropine hydrobromide 0.5 % Ophthalmic Drops

homatropine hydrobromide 0.5 % Ophthalmic Solution

homatropine hydrobromide 5 MG/ML Ophthalmic Solution


physostigmine sulfate 1 % Ophthalmic Solution

physostigmine sulfate 10 MG/ML Ophthalmic Solution


pilocarpine hydrochloride 0.1 % Ophthalmic Solution

pilocarpine HCl 0.1 % Ophthalmic Solution

pilocarpine hydrochloride 1 MG/ML Ophthalmic Solution


methacholine 25 MG/ML Ophthalmic Solution


dibucaine 1.1 % Topical Ointment
cinchocaine 1.1 % Topical Ointment


ISOtretinoin 0.0005 MG/MG Topical Gel
ISOtretinoin 0.05 % Topical Gel
isotretinoin 0.05 % Topical Gel


chlorhexidine gluconate 0.02 % Topical Spray

chlorhexidine gluconate 0.2 MG/ML Topical Spray


chlorhexidine gluconate 0.5 % / sodium nitrite 0.1 % Topical Solution

chlorhexidine gluconate 5 MG/ML / sodium nitrite 1 MG/ML Topical Solution


lidocaine hydrochloride 0.1 % Injectable Solution

lidocaine hydrochloride 1 MG/ML Injectable Solution


lidocaine hydrochloride 0.6 % Injectable Solution

lidocaine hydrochloride 6 MG/ML Injectable Solution


cocaine (as cocaine hydrochloride) 50 MG/ML Ophthalmic Solution


cocaine (as cocaine hydrochloride) 200 MG/ML Ophthalmic Solution


cocaine (as cocaine hydrochloride) 50 MG/ML / EPINEPHrine 0.2 MG/ML Ophthalmic Solution

cocaine 5 % / epinephrine 0.02 % Ophthalmic Solution

cocaine 5 % / EPINEPHrine 0.02 % Ophthalmic Solution

cocaine 50 MG/ML / EPINEPHrine 0.2 MG/ML Ophthalmic Solution

cocaine (as cocaine hydrochloride) 50 MG/ML / epinephrine 0.2 MG/ML Ophthalmic Solution

cocaine 50 MG/ML / epinephrine 0.2 MG/ML Ophthalmic Solution


1.8 ML Citanest 40 MG/ML Cartridge
Citanest Plain 4 % in 1.8 ML Cartridge

1.8 ML prilocaine hydrochloride 40 MG/ML Cartridge [Citanest]


bupivacaine hydrochloride 0.105 % Injectable Solution

bupivacaine hydrochloride 1.05 MG/ML Injectable Solution


EPINEPHrine 0.0125 MG/ML / lidocaine hydrochloride 20 MG/ML Injectable Solution

epinephrine 1:80,000 / lidocaine hydrochloride 2 % Injectable Solution

EPINEPHrine 1:80,000 / lidocaine hydrochloride 2 % Injectable Solution

epinephrine 0.0125 MG/ML / lidocaine hydrochloride 20 MG/ML Injectable Solution


atropine sulfate 0.031 % Ophthalmic Solution

atropine sulfate 0.31 MG/ML Ophthalmic Solution


atropine sulfate 0.062 % Ophthalmic Solution

atropine sulfate 0.62 MG/ML Ophthalmic Solution


atropine sulfate 0.1 % Ophthalmic Solution

atropine sulfate 1 MG/ML Ophthalmic Solution


atropine sulfate 0.125 % Ophthalmic Solution

atropine sulfate 1.25 MG/ML Ophthalmic Solution


atropine sulfate 0.25 % Ophthalmic Solution

atropine sulfate 2.5 MG/ML Ophthalmic Solution


atropine sulfate 500 MCG per 5 ML Oral Solution

atropine sulfate 0.1 MG/ML Oral Solution


Xylocaine-MPF 150 MG per 10 ML Injection

10 ML lidocaine hydrochloride 15 MG/ML Injection [Xylocaine]


A synthetic aminoethylamide with local anesthetic activity applied topically to either the skin or mucous membranes. Lidocaine stabilizes the neuronal cell membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses and producing a reversible loss of sensation.


A quaternary ammonium compound that serves as a long-acting cholinesterase inhibitor with parasympathomimetic activity. When used topically, demecarium inactivates both pseudocholinesterase and acetylcholinesterase, thereby preventing acetylcholine breakdown and increasing acetylcholine activity. This causes contraction of the iris sphincter muscle (producing miosis) and the ciliary muscle (affecting the accommodation reflex). In so doing, this agent increases the outflow of the aqueous humor, thereby reducing intraocular pressure.


fluocinolone acetonide 0.00625 % Topical Ointment

fluocinolone acetonide 0.0000625 MG/MG Topical Ointment


A synthetic topical glucocorticoid receptor (GR) agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Upon administration, mometasone binds to cytoplasmic GRs and subsequently activates GR-mediated gene expression. This results in the synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, mometasone appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.


Betadine 5 % Topical Spray
Betadine 50 MG/ML Topical Spray
BETADINE 5 % Topical Spray

povidone-iodine 50 MG/ML Topical Spray [Betadine]


soybean oil 300 MG/ML Injectable Suspension [Intralipid]


pyridostigmine bromide 60 MG Oral Tablet [Mestinon]


propamidine isethionate 0.15 % Ophthalmic Ointment

propamidine isethionate 0.0015 MG/MG Ophthalmic Ointment


diloxanide 250 MG / metroNIDAZOLE 200 MG Oral Tablet

diloxanide furoate 250 MG / metroNIDAZOLE 200 MG Oral Tablet

diloxanide 250 MG / metronidazole 200 MG Oral Tablet


benzoyl peroxide / erythromycin Topical Gel [Benzamycin]


zinc sulfate 220 MG Effervescent Oral Tablet


trihexyphenidyl HCl 2 MG in 5 mL Oral Solution

trihexyphenidyl HCl 2 MG per 5 ML Oral Solution

trihexyphenidyl hydrochloride 0.4 MG/ML Oral Solution


chlorproMAZINE hydrochloride 50 MG per 5 ML Oral Solution

chlorproMAZINE hydrochloride 10 MG/ML Oral Solution

chlorpromazine hydrochloride 50 MG per 5 ML Oral Solution

chlorpromazine hydrochloride 10 MG/ML Oral Solution


Retrovir 200 MG per 20 ML Injection
Retrovir 10 MG/ML per 20 ML Injection
Retrovir 200 MG in 20 ML Injection
20 ML AZT 10 MG/ML Injection [Retrovir]

20 ML zidovudine 10 MG/ML Injection [Retrovir]


trimethoprim 50 MG per 5 ML Oral Suspension


estradiol 0.0075 MG/24 HR 90 DAY Vaginal System

estradiol 0.000313 MG/HR 90 DAY Vaginal System

estradiol 7.5 MCG/24 HR 90 DAY Vaginal System

estradiol 2 MG (7.5 MCG per 24HR) 90 Day Vaginal System

90 DAY estradiol 0.000313 MG/HR Vaginal System


Prograf 5 MG per 1 ML Injection
Prograf 5 MG in 1 ML Injection

1 ML tacrolimus 5 MG/ML Injection [Prograf]


danthron 37.5 MG / poloxamer-188 500 MG Oral Capsule

danthron 37.5 MG / poloxamer 188 500 MG Oral Capsule


anthralin 0.11 % / coal tar 1 % / salicylic acid 1.6 % Topical Ointment

anthralin 0.0011 MG/MG / coal tar 0.01 MG/MG / salicylic acid 0.016 MG/MG Topical Ointment


Losartan Pot 50 MG Oral Tablet [Cozaar]
Cozaar 50 MG Oral Tablet
Losartan K+ 50 MG Oral Tablet [Cozaar]

losartan potassium 50 MG Oral Tablet [Cozaar]


Bactroban 0.02 MG/MG Nasal Ointment
Bactroban 2 % Nasal Ointment

mupirocin 0.02 MG/MG Nasal Ointment [Bactroban]


Valtrex (as valacyclovir hydrochloride) 500 MG Oral Tablet

valACYclovir 500 MG Oral Tablet [Valtrex]

Valtrex (as valACYclovir hydrochloride) 500 MG Oral Tablet

valacyclovir 500 MG Oral Tablet [Valtrex]


lamoTRIgine 200 MG Oral Tablet [LaMICtal]

lamotrigine 200 MG Oral Tablet [Lamictal]


Ritalin 10 MG Oral Tablet
Ritalin HCl 10 MG Oral Tablet

methylphenidate hydrochloride 10 MG Oral Tablet [Ritalin]


bicalutamide 50 MG Oral Tablet [Casodex]


pilocarpine hydrochloride 5 MG Oral Tablet [Salagen]


cycloSPORINE, modified 100 MG Oral Capsule [Neoral]

cyclosporine, modified 100 MG Oral Capsule [Neoral]


cycloSPORINE, modified 25 MG Oral Capsule [Neoral]

cyclosporine, modified 25 MG Oral Capsule [Neoral]


amitriptyline hydrochloride 10 MG/ML Oral Solution


propranolol hydrochloride 80 MG per 5 ML Oral Syrup

propranolol hydrochloride 16 MG/ML Oral Solution


chlorproMAZINE hydrochloride 25 MG per 5 ML Syrup

chlorproMAZINE hydrochloride 5 MG/ML Oral Solution

chlorpromazine hydrochloride 25 MG per 5 ML Syrup

chlorpromazine hydrochloride 5 MG/ML Oral Solution


phenytoin 90 MG per 5 ML Oral Suspension


oxybutynin chloride 1 MG/ML Oral Solution

oxybutynin chloride 5 MG per 5 ML Oral Solution

oxybutynin chloride 5 MG in 5 mL Oral Solution


ipratropium Br 0.5 MG / albuterol sulfate 3 MG in 3 ML Inhalation Solution

albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution

albuterol 2.5 MG (as albuterol sulfate 3 MG) / ipratropium bromide 0.5 MG per 3 ML Inhalation Solution


Iopidine 5 MG/ML (apraclonidine hydrochloride 5.75 MG/ML) Ophthalmic Solution

apraclonidine 5 MG/ML Ophthalmic Solution [Iopidine]


ReoPro 10 MG per 5 ML Injection
ReoPro 10 MG in 5 ML Injection

5 ML abciximab 2 MG/ML Injection [ReoPro]


lactic acid 25 % / salicylic acid 25 % Topical Ointment

salicylic acid 25 % / lactic acid 25 % Topical Ointment

lactic acid 0.25 MG/MG / salicylic acid 0.25 MG/MG Topical Ointment


salicylic acid 5 % / zinc oxide 20 % Topical Powder

Salicylic Acid 0.05 MG/MG / ZNO 0.2 MG/MG Topical Powder

salicylic acid 0.05 MG/MG / zinc oxide 0.2 MG/MG Topical Powder


silver nitrate 20 % Topical Solution
AgNO3 200 MG/ML Topical Solution

silver nitrate 200 MG/ML Topical Solution


AgNO3 400 MG/ML Topical Solution
silver nitrate 40 % Topical Solution

silver nitrate 400 MG/ML Topical Solution


Dovonex (as calcipotriene monohydrate) 0.005 % Topical Cream

calcipotriene 0.05 MG/ML Topical Cream [Dovonex]


TNG 0.4 MG/ACTUAT Mucosal Spray [Nitrolingual]

NTG 0.4 MG/ACTUAT Mucosal Spray [Nitrolingual]

Nitrolingual 0.4 MG/ACTUAT Mucosal Spray

nitroglycerin 0.4 MG/ACTUAT Mucosal Spray [Nitrolingual]


Fosamax 10 MG (as alendronate sodium 13.1 MG) Oral Tablet

alendronic acid 10 MG Oral Tablet [Fosamax]


A 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.


The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins. As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.


Tanacetum parthenium whole extract
feverfew extract


The essential oil from the leaves of Melaleuca leucadendra. Cajaput oil is used as an expectorant, for treatment of tooth and gum pain, and for its antiseptic properties.


A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.


A progestogen-like compound used as a cattle feed additive for its growth promoting effects and suppression of estrus (heat) in heifers. Critics have claimed that hormones used as growth promotants in cattle may cause breast cancer. (NCI)


A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.


A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.


The sodium salt form of an organic phosphate compound that provides phosphate for nutritional purposes. In addition, sodium glycerophosphate can be used as a phosphate diluting agent upon internal contamination with the beta-emiting radioisotope phosphate P 32 (P-32) that competes with P-32 for absorption. As sodium glycerophosphate is administered in high amounts, the absorption of P-32 is prevented or minimalized.


The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent. (NCI04)


A synthetic recombinant form of the naturally occurring hirudin, the anticoagulant substance found in leech. Desirudin is a selective and almost irreversible inhibitor of thrombin, both free and clot-bound, by blocking its active site. This anticoagulant agent has no effect on other components of the hemostatic system. Desirudin is particularly used to prevent deep vein thrombosis in patients undergoing hip and knee replacement surgery.


A tolyl compound and leukotriene receptor antagonist (LTRA), with anti-asthmatic and potential capsular contracture-preventing activities. Upon administration, zafirlukast selectively and competitively binds to and blocks the cysteinyl leukotriene 1 receptor (CYSLTR1), thereby preventing the potent pro-inflammatory mediators leukotriene C4, D4 and E4 from binding. This prevents leukotriene-mediated actions, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, inflammation, capillary permeability and bronchoconstriction. In addition, zafirlukast may decrease collagen deposition, fibrosis, and capsular thickness after implantation, thereby preventing scar tissue.


A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.


A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)


A combination agent, comprised of belladonna alkaloids and Phenobarbital, with gastrointestinal anticholinergic activity. The belladonna alkaloids produce an anticholinergic effect by the competitive inhibition of acetylcholine at the parasympathetic neuro-effector junction, and the barbiturates produce a sedative effect probably as a result of their inhibition of synaptic neurotransmitters in the central nervous system (CNS).


The recombinant analog of endogenous beta (B) chain of the cytokine platelet-derived growth factor (PDGF). Synthesized primarily by megakaryocytes, endogenous PDGF consists of two related peptide chains, PDGF-A and PDGF-B. PDGF functions as a local autocrine and paracrine growth factor in many cellular processes. Recombinant PDGF, alone and in combination with other agents, may be useful in promoting bone formation and soft tissue repair. (NCI04)


A synthetic light-activated chlorin with photodynamic activity. Upon systemic administration, temoporfin distributes throughout the body and is taken up by tumor cells. Upon stimulation of temoporfin by non-thermal laser light (at 652 nm), and in the presence of oxygen, this agent produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to tumor cells. This may kill tumor cells and may reduce the tumor size.


A third-generation amino-bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Ibandronic acid binds to and adsorbs onto the surface of hydroxyapatite crystals in the bone matrix, thereby preventing osteoclast resorption. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in the mevalonate pathway. Inhibition of this enzyme prevents the formation of isoprenoids, thereby leading to a reduction in the farnesylation and geranylgeranylation of signaling proteins of G protein-coupled signaling, and, eventually, inducing apoptosis of osteoclasts. By inhibiting osteoclast-mediated bone resorption, ibandronic acid increases bone mineral density, decreases bone remodeling and turnover, as well as reduces bone pain.


An indium 111 radioconjugate of pentetreotide, the diethylenetriaminopentaacetic (DTPA) conjugate of the human hormone somatostatin peptide analogue (octreotide), used for radioimaging neuroendocrine tumor cells. The pentetreotide moiety of indium In 111 pentetreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate allows for specific imaging of neuroendocrine tumors that overexpress somatostatin using scintigraphic imaging techniques. In addition, high dose indium In 111 pentetreotide may specifically deliver a cytotoxic dose of gamma radiation to SSTR-positive cells thereby killing SSTR-expressing tumor cells.


The hydrochloride salt form of ziprasidone, a benzothiazolylpiperazine derivative and an atypical antipsychotic agent with an antischizophrenic property. Ziprasidone hydrochloride functions as an antagonist at the dopamine D2 and serotonin 5-HT2A and 5-HT1D receptors, and as an agonist at the 5-HT1A receptor. Ziprasidone hydrochloride also inhibits synaptic reuptake of serotonin and norepinephrine. The mechanism of action by which ziprasidone hydrochloride exerts its antischizophrenic effect is unknown but is potentially mediated through a combination of dopamine D2 and serotonin 5-HT2 antagonism. This agent also has antagonistic activity against histamine H1 and alpha-1-adrenergic receptors.


A benzothiazolylpiperazine derivative and an atypical antipsychotic agent with an antischizophrenic property. Ziprasidone functions as an antagonist at the dopamine D2 and serotonin 5-HT2A and 5-HT1D receptors, and as an agonist at the 5-HT1A receptor. Ziprasidone also inhibits the synaptic reuptake of serotonin and norepinephrine. The mechanism of action by which ziprasidone exerts its antischizophrenic effect is unknown but is potentially mediated through a combination of dopamine D2 and serotonin 5-HT2 antagonism. This agent also has antagonistic activity against histamine H1 and alpha-1-adrenergic receptors.


The orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.


Any monoclonal antibody directed against the cell surface glycoprotein CD52, regardless of the antibody type (e.g., rat, mouse, humanized).


An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.


A synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.


A benzoporphyrin derivative that is used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION.


respiratory syncytial virus immune globulin intravenous

respiratory syncytial virus immune globulin, intravenous


The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, fingolimod, as a structural analogue of sphingosine, selectively targets and binds to S1PR1 on lymphocytes and causes transient receptor activation followed by S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes. fingolimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Fingolimod also shifts macrophages to an anti-inflammatory M2 phenotype, and modulates their proliferation, morphology, and cytokine release via inhibition of the transient receptor potential cation channel, subfamily M, member 7 (TRPM7).


A benzhydryl compound and a muscarinic receptor antagonist possessing both antimuscarinic and antispasmodic properties. Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, competitively blocks muscarinic receptors, thereby inhibiting acetylcholine binding. This antagonistic action results in an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, indicating an antimuscarinic action on the lower urinary tract. The 5-hydroxymethyl metabolite appears to contribute significantly to the therapeutic effects.


A broad-spectrum, carbapenem antibiotic with bactericidal and beta-lactamase resistant activities. Doripenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, particularly PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and eventually lysis of the bacterial cell wall. This agent is two- to 16-fold more potent than imipenem and comparable to ertapenem and meropenem.


A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)


A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.


A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.


The flower-heads of either the plant Anthemis nobilis or the plant Matricaria chamomilla. Chamomile has a warm aromatic odour and a very bitter taste and contains volatile oils which are a mixture of butyl and amyl angelates and valerates. Due to its coumarin constituents, large doses may interfere with coagulation. (NCI04)


The essential oil of Cananga odorata. Cananga oil is used primarily in aromatherapy preparations.


An aliphatic carboxylic acid, also known as enanthic acid, used in the synthesis of esters for products such as fragrances and artificial flavor preparations.


The oil extracted from the seeds of grapes. Grape seed oil is used in cooking and cosmetics and for medicinal purposes.


succinylated gelatin 4 % Injectable Solution

succinylated gelatin 40 MG/ML Injectable Solution


A spray intended for administration to the mucosa of the nose.


brand name of zolpidem, a drug used to treat insomnia


torsemide 50 MG in 5 ML Injection
torsemide 50 MG per 5 ML Injection


The trisodium salt form of calcium diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination with any of these radionuclides thereby increasing their excretion.


The levoisomer of nordefrin, a synthetic catecholamine and norepinephrine derivative with sympathomimetic and antihypertensive effects. Levonordefrin's antihypertensive effect is exerted through activation of alpha 2-adrenergic receptors in the cardiovascular control center of the CNS thereby suppressing the sympathetic output from the brain and subsequently lowering blood pressure. Levonordefrin binds to and activates peripheral alpha 2- adrenergic receptors, thereby causing vasoconstriction.


An orally available precursor of decanoic acid (DA), a 10-carbon fatty acid and major component of medium chain triglyceride oils, with potential antiandrogen and antihyperglycemic properties. Upon oral administration, tricaprin is hydrolyzed to DA, which binds to and partially activates peroxisome proliferator-activated receptor (PPAR)-gamma, as well as PPAR-alpha and PPAR-beta/delta, without inducing adipogenesis. Additionally, tricaprin may improve insulin sensitivity and decrease androgen production.


The potassium salt form of phenethicillin, a narrow-spectrum, beta-lactamase-sensitive penicillin with antibacterial activity. Phenethicillin binds to and inactivates the penicillin binding proteins (PBPs) located inside the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.


The benzathine salt form of cephapirin, a semisynthetic, broad-spectrum, first-generation cephalosporin with antibacterial activity. Cephapirin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.


The hydrochloride salt form of ceftiofur, a semisynthetic, beta-lactamase-stable, broad-spectrum, third-generation cephalosporin with antibacterial activity. Ceftiofur binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.


The hydrochloride salt form of pirlimycin, a derivative of clindamycin with a 6-membered ring replacing clindamycin's 5-membered ring. Compared to clindimycin, pirlimycin has increased activity against gram-positive bacteria, including Staphylococcus aureus and coagulase negative species of Staphylococcus and Streptococcus. This agent is primarily used in the treatment of mastitis in cattle.


A protein extract of human menopausal urine in which LUTEINIZING HORMONE has been partially or completely removed. Urofollitropin represents FOLLICLE STIMULATING HORMONE from the urine.


The sodium salt of a semisynthetic heparin-like glucosaminoglycan. Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties. In addition, pentosan polysulfate may block endothelial P-selectin and increase microvascular blood flow in sickle cell disease.


The magnesium salt of valproic acid (2-propylpentanoic acid) with antiepileptic and potential antineoplastic activities. Magnesium valproate dissociates in the gastrointestinal tract and is absorbed into the circulation as magnesium ions and valproic acid ions; valproic acid may inhibit histone deacetylases, inducing tumor cell differentiation, apoptosis, and growth arrest. In addition, valproic acid exerts an antiepileptic effect, likely by inhibiting enzymes that catabolize the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) catabolism and so increasing concentrations of GABA in the central nervous system (CNS). The presence of the magnesium in this agent may contribute to its anticonvulsant activity and sedative properties.


An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Iobenguane localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.


A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.


A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.


An imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine also enhances the uveoscleral outflow of aqueous humor. This reduces intraocular pressure.


The nitrate salt form of omoconazole, a topical imidazole derivative with antifungal activity against Candida albicans, Malassezia furfur and dematophytes.


A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.


A docosanoid and a structural analogue of an inactive biosynthetic cyclic derivative of arachidonic acid, 13,14-dihydro-15-keto-prostaglandin F 2a. Although the mechanism of action is unknown, unoprostone isopropyl may reduce elevated intraocular pressure by increasing the outflow of aqueous humor upon ocular administration.


A dual action selective histamine H1 receptor antagonist and mast cell stabilizer with anti-allergic activity. Olopatadine stabilizes mast cells and prevents histamine release from mast cells. In addition, this agent also blocks histamine H1 receptors, thereby preventing histamine from binding to these receptors. Both actions prevent the effects of histamine on capillaries, bronchial smooth muscle, and gastrointestinal (GI) smooth muscle, including histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of GI smooth muscle. This drug also prevents histamine-induced pain and itching of mucous membranes.


The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity. This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases.


A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. After hydrolysis of candesartan cilexetil to candesartan during gastrointestinal absorption, candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.


A synthetic lipid-lowering agent. Cerivastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing major histocompatibility complex II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Muscle toxicity (myopathy and rhabdomyolysis) precludes the clinical use of this agent.


A member of the triptan class of agents with anti-migraine properties. Zolmitriptan selectively binds to and activates serotonin (5-HT) 1B receptors expressed in intracranial arteries and 5-HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brainstem sensory nuclei. Receptor binding results in constriction of cranial vessels, reduction of vessel pulsation and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Zolmitriptan may also relieve migraine headaches by inhibition of pro-inflammatory neuropeptide release.


An immunoconjugate of the murine monoclonal antibody, 7E11-C5.3 (Capromab), conjugated to the linker-chelator, glycyl-tyrosyl-(N,-diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYK-DTPA-HCl). Capromab, an IgG1 kappa immunoglobulin, binds specifically to a cytoplasmic epitope of prostate-specific membrane glycoprotein (PSMA) that is only expressed by prostatic epithelial cells (benign and malignant). Capromab pendetide can be used in diagnosis or detection of prostate cancer when labeled with Indium I-111, which emits gamma radiation and X-Ray photons that can be captured by gamma camera allowing imaging of PMSA expressing tissues.


An orally bioavailable pyrazolopyrimidinone derivative structurally related to zaprinast, with vasodilating and potential anti-inflammatory activities. Upon oral administration, sildenafil selectively targets and inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), thereby inhibiting the PDE5-mediated degradation of cGMP found in smooth muscle and increasing cGMP availability. This results in prolonged smooth muscle relaxation in the corpus cavernosum of the penis, thereby causing vasodilation, blood engorgement and a prolonged penile erection. In the smooth muscle of the pulmonary vasculature, the increase in cGMP results in smooth muscle relaxation, vasodilation of the pulmonary vascular bed, relieving pulmonary hypertension and increasing blood flow in the lungs. In addition, sildenafil may reduce airway inflammation and mucus production.


The besylate salt form of cisatracurium, a non-depolarizing skeletal muscle relaxant of the benzylisoquinolinium class, with skeletal muscle relaxing activity. Cisatracurium besylate acts as a competitive acetylcholine antagonist that binds to nicotinic receptors at the neuromuscular junction. This blocks neuromuscular transmission and causes neuromuscular relaxation.


A fluorene derivative that is used in combination with ARTEMETHER for the treatment of MALARIA (see ARTEMETHER-LUMEFANTRINE DRUG COMBINATION).


A fluoroquinolone antibiotic with antimicrobial property. Gemifloxacin enters bacterial cells by diffusion through integral membrane porin pathway before targeting both DNA gyrase and topoisomerase IV, two enzymes critical for DNA replication and repair. This agent binds to the DNA/DNA-gyrase complex and inhibits the A subunits of the enzyme thereby preventing the bacterial chromosome from rejoining. This interferes with DNA replication and repair processes as well as transcription, and ultimately leads to bacterial cell death. Gemifloxacin targets at both Gram-positive, -negative and atypical human pathogens.


A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.


An orally bioavailable synthetic analog of the neuroactive steroid allopregnanolone and positive allosteric modulator of the gamma-aminobutyric acid (GABA)-A receptor, with anxiolytic, sedative, antidepressant and anticonvulsant activities. Upon oral administration, ganaxolone specifically targets and binds to the allosteric sites of the synaptic and extrasynaptic GABA-A receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization, increases the inhibitory effect of GABA on the CNS, and inhibits neurotransmission. This blocks seizure propagation and elevates seizure thresholds.


A long-lasting, recombinant version of human insulin. It is an insulin analogue with myristic acid bound to the lysine at position B29 and a deletion of B30.


A short polypeptide with activity against human immunodeficiency virus (HIV). Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 viral envelope glycoprotein, thereby preventing conformational changes required for fusion of viral and cellular membranes and preventing the virus from entering a host cell.


A peptide analogue of human amylin with 3 proline substitutions at positions 25, 28 and 29, with antihyperglycemic activity. By mimicking amylin, pramlintide slows gastric emptying, inhibits digestive secretions (gastric acid, pancreatic enzymes, and bile), reduces glucagon secretion, and increases satiety; all of these actions are mediated mostly by glucose-sensitive areas in the brain stem. The overall result is a decrease in blood glucose levels. The use of pramlintide may cause an increased risk of insulin-induced hypoglycemia.


A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)


A cyclic lipopeptide echinocandin and beta-(1,3)-D-glucan synthase inhibitor that is used to treat internal or systemic MYCOSES.


A glucan that is structurally related to maltodextrin, with more than 85% of its molecules having molecular weights between 1640 and 45 000 Daltons (Da), and a weight-average molecular weight of about 20 000 Da; it is used in dialysis fluids as an alternative to glucose-based solutions, and to reduce adhesions after gynecological or abdominal surgery. It has also been used as a vehicle for drugs given via the peritoneal cavity.


A hematopoietic growth factor with activity on mature and immature hematopoietic progenitor cells.


A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.


An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.


A dipivoxil formulation of adefovir, a nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).


An allylamine derivative that binds BILE ACIDS in the intestine and is used as an ANTICHOLESTEREMIC AGENT in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.